跳至主要内容
临床试验/NCT00665431
NCT00665431已完成3 期

Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Center Study Evaluating the Efficacy of PN400 (VIMOVO) Twice Daily (Bid) and Celecoxib Once Daily (qd) in Patients With Osteoarthritis of the Knee

POZEN1 个研究点 分布在 1 个国家目标入组 610 人开始时间: 2008年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
610
试验地点
1
主要终点
Change in Western Ontario and McMaster Universities (WOMAC) Function Questionnaire Subscore From Baseline

研究概览

简要总结

We will evaluate the efficacy of PN 400 and an active comparator in patients that have Osteoarthritis of the knee.

详细描述

3-Month study in subjects 50 years and older with osteoarthritis of the knee. Assessments Western Ontario and McMaster Universities (WOMAC) pain and function and patient global assessment scales.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Arm 1 PN 400 (VIMOVO)

Experimental

PN400: 500 mg naproxen/20 mg esomeprazole bid

干预措施: Rescue Antacid (Drug)

Arm 1 PN 400 (VIMOVO)

Experimental

PN400: 500 mg naproxen/20 mg esomeprazole bid

干预措施: PN 400 (VIMOVO) (Drug)

Arm 2 (Celebrex)

Active Comparator

Celecoxib 200 mg

干预措施: celebrex (Drug)

Arm 2 (Celebrex)

Active Comparator

Celecoxib 200 mg

干预措施: Rescue Antacid (Drug)

Arm 3 (Placebo)

Placebo Comparator

sugar pill

干预措施: Placebo (Other)

Arm 3 (Placebo)

Placebo Comparator

sugar pill

干预措施: Rescue Antacid (Drug)

结局指标

主要结局

Change in Western Ontario and McMaster Universities (WOMAC) Function Questionnaire Subscore From Baseline

时间窗: 12 Weeks

WOMAC function questionnaire (VAS). The 17 questions about function all use visual analog scale (VAS) of 100 mm; 0 mm being "no pain" and 100 mm being "extreme pain". The outcome measures a change in WOMAC pain from baseline (in mm). The Western Ontario and McMaster Universities (WOMAC) is a self-administered, patient-reported health status questionnaire that is designed to capture elements of pain, stiffness and physical disability in patients with OA of the knee and/or hip joints. The index consists of 24 questions (5 questions about pain, 2 on stiffness and 17 about physical function).

Change in Patient Global Assessment (PGA) Subscore From Baseline

时间窗: 12 Weeks

PGA questionnaire. The patient global assessment (PGA) question asks about how the subject is doing considering his/her arthritis and is measured by a visual analog scale (VAS); 0 mm (very poor) 100 mm (excellent). The outcome measures a change from baseline PGA in mm.

Change in Western Ontario and McMaster Universities (WOMAC) Pain Questionnaire Subscore From Baseline

时间窗: Baseline and 12 Weeks

Western Ontario and McMaster Universities (WOMAC) pain questionnaire has 5 questions on pain all use visual analog scale (VAS) of 100 mm, with 0 mm being "no pain" and 100 mm being "extreme pain". The outcome measures a change in WOMAC pain at 12 weeks from baseline (in mm). WOMAC is a self-administered, patient-reported health status questionnaire designed to capture elements of pain, stiffness and physical disability in patients with OA of the knee and/or hip joints. It consists of 24 questions (5 questions about pain, 2 on stiffness and 17 about physical function).

次要结局

  • Change in Western Ontario and McMaster Universities (WOMAC) Pain Questionnaire Subscore From Baseline(Week 6)
  • Change in Western Ontario and McMaster Universities (WOMAC) Function Questionnaire Subscore From Baseline(Week 6)
  • Change in Patient Global Assessment (PGA) Subscore From Baseline(Week 6)
  • Mean Change From Baseline in American Pain Society Patient Outcome Questionnaire (APS-POQ)Total Interference Caused by Pain.(Baseline and Day 7)
  • Antacid Tablet Use(12 weeks)
  • Percent of Days With no Heartburn (Heartburn Resolution)(12 weeks)
  • Modified Severity of Dyspepsia Assessment (mSODA)(12 weeks)
  • Number of Participants Reporting Pre-specified Non-steroidal Antiinflammatory Drug-associated Upper Gastrointestinal (UGI) Symptoms(daily during 12 weeks)
  • The Number of Subjects Who Discontinued From the Study Due to Any Pre-specified Non-steroidal Antiinflammatory Drug-associated Upper Gastrointestinal Adverse Event(daily during 12 weeks)

研究者

发起方
POZEN
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验

Efficacy Study of PN400 (VIMOVO) Twice Daily and... | 临床试验